The Food and Drug Administration has issued a Public Health Advisory alerting doctors who perform heart bypass surgery, and their patients, that Trayslol (aprotinin injection), a drug used to prevent blood loss during surgery, has been linked to higher risks of serious side effects including kidney problems, heart attacks and strokes in patients who undergo artery bypass graft surgery.